Valsartan is angiotensin receptor blocker used by millions of Americans to treat high blood pressure. In July of 2018, the FDA had announced a voluntary recall of several drugs containing valsartan. This recall was because of contamination with an impurity, the possible carcinogen and hepatotoxic chemical N-nitrosodimethylamine, or NDMA. NDMA consumption has been associated with either liver or lung cancer. NDMA previously was used to make rocket fuel, however this stopped after dangerously high levels of this chemical compound were found in air, water, and soil samples collected near a rocket fuel manufacturing plant. NDMA can be unintentionally formed during various manufacturing processes at many industrial sites. It can also found in the air, water and soil from reactions involving other chemicals called alkylamines. The FDA had traced the recalled drugs to Chinese manufacturers Zhejiang Huahais and Zhejiang Tianyu as well as Hetero Labs Limited in India. In September of 2018, the FDA had found another toxic chemical in valsartan batches called N-nitrosodiethylamine (NDEA). Combinations drugs such as (amlodipine and valsartan) (amlodipine, valsartan and hydrochlorothiazide), and (valsartan and hydrochlorothiazide) were also effected. Other medications in the ARB class, such as losartan and irbesartan were also found to have these contaminants.